logo
#

Latest news with #EIR

Powys council misses information request deadlines
Powys council misses information request deadlines

Powys County Times

timea day ago

  • Politics
  • Powys County Times

Powys council misses information request deadlines

The number of requests for information met on time by Powys County Council plummeted during 2023/4, a meeting has heard. At a meeting of Powys County Council's Liberal Democrat/Labour Cabinet senior councillors received a historic annual report on Information Governance covering 2023/2024. The report showed that during that year the council received a total of 1,271 information requests under the Freedom of Information (FOI) Act, Environmental Information Regulations (EIR) and Subject Access Requests (SAR), 16 per cent up on the 1,093 received in 2022/2023. FOI and EIR requests are supposed to receive an answer within 20 working days while for SAR the deadline is 30 days. The performance during 2023/2024 saw was 73 per cent for FOI, 77 per cent for EIR and for SARs only 32 per cent were completed on time. This is down on the 84 per cent for both FOI and EIRs and 57 per cent for SARs that the council achieved in 2022/2023. The Information Commissioner expects the compliance rate to be at 90 per cent. The report explains that the team have had staffing issues during the reporting period. Cllr Raiff Devlin (Liberal Democrat) who was installed as the cabinet member customers, digital and customer services only last month said that an 'Information Management, Assurance, and Governance plan' was in place to try and improve things. As of the end of March last year only 35 per cent of this plan had been completed. Cllr Devlin said: 'Further work is required to meet the targets. 'Compliance rates have seen a decline, and this is as a result of resource challenges within the department. '66 per cent of non-compliant responses were due to delays in the provision of information by the service enabling a response to be drafted or released. 'Complaints to the commissioner are mainly linked to late requests.' 'The commissioner made decisions on two complaints, over an exemption applied and information held. 'The commissioner found in favour of the council on both occasions.' He said that the report provided 'reasonable assurance' that the council's arrangements and plan 'adequately' reflect the principles of good information governance. Cllr Devlin added: 'It is important to note that this report is from 2023/2024 and many of the forward plan priorities have already been actioned by the department and that the 2024/2025 report is in development.'

This smallcap stock zooms 105% from April low, hits new high; here's why
This smallcap stock zooms 105% from April low, hits new high; here's why

Business Standard

time2 days ago

  • Business
  • Business Standard

This smallcap stock zooms 105% from April low, hits new high; here's why

India Glycols share price Share price of India Glycols hit a new high of ₹2,057, gaining 2 per cent on the BSE in Thursday's intra-day trade. The stock price of the breweries & distilleries company has more-than-doubled or zoomed 105 per cent from its three-month low of ₹1,005 touched on April 7, 2025. In the past one week, India Glycols has appreciated by 14 per cent, as compared to a 2.4 per cent rise in the BSE Sensex. What's driving stock price of India Glycols The board of directors of India Glycols at its meeting held on May 30, 2025 approved the sub-division/split of the 1 equity share having face value of ₹10 each, into 2 equity shares, having face value of ₹5 each. India Glycols said the rationale behind the split is to enhance the liquidity of company's equity shares in the capital market and to encourage wider participation of investors by making equity shares of the company more affordable. Meanwhile, for the March 2025 quarter (Q4FY25), India Glycols reported strong operational performance with earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 35.1 per cent to ₹148 crore from ₹109 crore in Q4FY24. Margins reported a healthy improvement of 532 bps to 17.1 per cent from 11.7 per cent in a year ago quarter. JV reported a strong performance for the full year, with Net Revenue grew by 13 per cent and EBITDA up 70 per cent as compared to FY24, primarily supported by reduced Ethylene Oxide (EO) price gap and product-mix improvement. The company saw strong growth in Country Liquor (CL) and Indian Made Foreign Liquor (IMFL), focusing on premiumisation and penetration into newer markets, supported by partnership with Amrut. Meanwhile, the company said it has been allocated quantities through tender(s) participation for supply of 180.6 million liters of Ethanol with an estimated value aggregating to ₹1,264 crore under Ethanol Blended Petrol Programme (EBPP) for Ethanol Supply Year 1-November-2024 till 31-October-2025. In another development, India Glycols has received the Establishment Inspection Report (EIR) with no observation from US Food and Drug Administration (USFDA) on April 25, 2025 for the company's nutraceutical products and dietary supplements ingredients at Dehradun Plant. The company said the receipt of EIR underscores its commitment to adhering to global quality standards and paves the way for access to the premium the US market, along with other highly regulated global markets. About India Glycols India Glycols is one of the leading manufacturers of Bio-based Specialties & Performance Chemicals (BSPC), Biofuel, Potable Spirits (PS) and Ennature Biopharma (EB). It is the first company in the world to produce Ethylene Oxide (EO) / Mono Ethylene Glycol (MEG) from renewable Agro routes based on molasses since 1989. The company has a diversified portfolio with exposure in Bio-based Specialties, Bio-Polymers, Plant based APIs & Nutraceuticals, Potable Spirits, Gases, Biofuels, and others. The company has a global presence and partners in various countries, with a rich legacy of over three decades in innovation and sustainability.

Egypt's Travel & Tourism Sector contributes EGP 1.4 Trillion to GDP in 2024 : WTTC
Egypt's Travel & Tourism Sector contributes EGP 1.4 Trillion to GDP in 2024 : WTTC

Tourism Breaking News

time2 days ago

  • Business
  • Tourism Breaking News

Egypt's Travel & Tourism Sector contributes EGP 1.4 Trillion to GDP in 2024 : WTTC

Post Views: 52 According to WTTC's latest Economic Impact Research (EIR), developed in collaboration with Oxford Economics, the sector contributed EGP 1.4TN to Egypt's GDP in 2024, accounting for 8.5% of the national economy. Looking ahead, 2025 is projected to set a new all-time high with a forecast annual growth of 4.9% and increase in the sector's share to 8.6% of national GDP. This underlines the central role of Travel & Tourism in Egypt's continued economic development. 2024 also marked the strongest year on record for visitor spending. International visitor expenditure reached EGP 726.9BN, up 36.1% compared to 2019, while domestic visitor spending rose to EGP 449.9BN, 31.8% above pre-pandemic levels. This upward trend is set to continue. In 2025, international visitor spending is projected to increase to EGP 768.2BN, and domestic spending is expected to reach EGP 460.6BN, maintaining the country's strong recovery and sustained demand across both international and local travel. In addition to record-breaking economic contribution and visitor spending, in 2024, the sector supported 2.7 million jobs, exceeding the 2019 peak. This growth is set to continue, with 2025 employment forecast to rise to 2.9 million, marking a 22.3% increase compared to 2019. Julia Simpson, WTTC President & CEO, said: 'Egypt's Travel & Tourism sector is experiencing a powerful resurgence, with record-breaking economic contribution and a sustained surge in visitor spending. These numbers reflect a sector on the rise: dynamic, resilient, and vital to the country's growth. 'With its rich cultural heritage, world-class attractions, and growing connectivity, Egypt continues to captivate travellers from around the globe. The government's focus on investment, infrastructure, and sustainable tourism is clearly paying off.' WTTC forecasts a decade of sustained expansion for Egypt's Travel & Tourism sector. By 2035, the sector is expected to contribute EGP 2.1TN to the national economy, accounting for 8.4% of GDP. Employment is projected to reach 3.8 million jobs, representing 10.5% of total employment, and highlighting the sector's critical role in job creation. Over the same period, international visitor spending is expected to rise to EGP 1.1TN, while domestic spending is forecast to reach EGP 627BN, reflecting Egypt's potential to become one of the region's most vibrant and sustainable tourism economies.

Gland Pharma facility in Vizag recieves EIR from U.S. FDA
Gland Pharma facility in Vizag recieves EIR from U.S. FDA

The Hindu

time4 days ago

  • Business
  • The Hindu

Gland Pharma facility in Vizag recieves EIR from U.S. FDA

Gland Pharma's facility in Visakhapatnam, which was earlier this year issued Form 483 with three observations by the U.S. Food and Drug Administration, has since received an establishment inspection report from the agency, the generic injectable focussed company said on Tuesday, a development that saw its shares close 1.43% higher at ₹1,768.75 apiece on the BSE. The receipt of the EIR indicates closure of the U.S. FDA inspection conducted in February, the company said in a filling. A pre-approval inspection (PAI) for sterile active pharmaceutical ingredients (APIs), the U.S. FDA had inspected the facillity from February 19-25 and on conclusion issued a Form 483 with three observations. The company had then said the observations are procedural in nature and it will submit the corrective and preventive actions to the agency within the stipulated period. The observations issued are neither repeated observations nor related to data integrity, Gland Pharma had said.

Gland Pharma jumps 3% in trade; here's what is boosting investor interest
Gland Pharma jumps 3% in trade; here's what is boosting investor interest

Business Standard

time4 days ago

  • Business
  • Business Standard

Gland Pharma jumps 3% in trade; here's what is boosting investor interest

Gland Pharma shares gained 3.2 per cent in trade on Tuesday, logging an intraday high at ₹1,800 per share on BSE. The stock was in demand after the company received an Establishment Inspection Report (EIR) from the US Food and Drugs Administration (US FDA) for its facility at JNPC, Visakhapatnam. At 12:12 PM, Gland Pharma share price was trading 2.08 per cent higher at ₹1,780 per share on the BSE. In comparison, the BSE Sensex was up 1.34 per cent at 82,993.55. The company's market capitalisation stood at ₹29,326.64 crore. Its 52-week high was at ₹2,220.95 per share and 52-week low was at ₹1,200 per share. "This is to inform you that following the Pre-approval inspection (PAI) for Sterile APIs at the Company's Facility at JNPC, Visakhapatnam between February 19, 2025, and February 25, 2025; the Company has received an Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection," the filing read. EIR is a document generated by the US FDA or other regulatory authorities after they conduct an inspection of a pharmaceutical manufacturing facility. The EIR serves as an official record of the company's compliance with Good Manufacturing Practices (GMP), safety protocols, and regulatory requirements. A positive EIR (indicating compliance) shows that the company meets the necessary standards to produce drugs safely and effectively. Recently, Gland Pharma secured USFDA approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL. Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Giapreza of La Jolla Pharma LLC, the company revealed. About Gland Pharma Gland Pharma is a small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world. Gland Pharma has seven manufacturing facilities in India, comprising four facilities for finished formulations and three API facilities. We are focused on meeting diverse injectables needs with a stable supply of affordable and high-quality products. We have established a portfolio of injectables products across various therapeutic segments and delivery systems and are present in sterile injectables, oncology and ophthalmics with a focus on complex injectable

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store